GlassScriptPhysician profile
Christopher Schrodt
NPI 1730309188
$1,605.67
in general payments reported to CMS, 2019-2025
15 companies · $32.28 in 2025
The $32.28 reported for 2025 was less than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $300 · 2020: $32.27 · 2021: $297 · 2022: $227 · 2023: $448 · 2024: $268 · 2025: $32.28.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $744 · Education: $5.17.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $743.76 |
| Education | $5.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $540.34 | 2021-2025 | Vraylar |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $222.60 | 2021-2023 | |
| Supernus Pharmaceuticals, INC. | $215.45 | 2023-2024 | Qelbree, Qelbree |
| Ironshore Pharmaceuticals INC. | $132.53 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $131.07 | 2022-2025 | Trintellix |
| Janssen Pharmaceuticals, INC | $130.84 | 2019-2022 | |
| Sunovion Pharmaceuticals INC. | $79.09 | 2021-2022 | |
| Bausch Health US, LLC | $35.89 | 2021-2022 | |
| Axsome Therapeutics, INC. | $22.33 | 2023 | Auvelity |
| Avanir Pharmaceuticals, INC. | $20.13 | 2019 | |
| Lundbeck LLC | $19.74 | 2020 | |
| Teva Pharmaceuticals USA, INC. | $14.66 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $14.42 | 2023 | Nuedexta |
| Shire North American Group INC | $14.05 | 2019 | |
| Adlon Therapeutics L.P. | $12.53 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Schrodt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.